延长静脉注射双膦酸盐疗法在预防癌症患者骨骼并发症中的应用。
Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
作者信息
Crawford Brooke S, McNulty Robert M, Kraut Eric H, Turowski Robert C
机构信息
Department of Pharmacy, The Ohio State University Medical Center, 410 West 10th Avenue, Columbus, OH 43235, USA.
出版信息
Cancer Invest. 2009 Dec;27(10):984-8. doi: 10.3109/07357900902783203.
PURPOSE
To evaluate the incidence of skeletal complications in patients with multiple myeloma, and metastatic breast, prostate, or lung cancers, when therapy with intravenous bisphosphonates is continued for longer than 21 months.
METHODS
The primary outcome was the diagnosis of at least one skeletal-related event (SRE) after 21 months of therapy. The secondary outcome was the incidence of osteonecrosis of the jaws (ONJ).
RESULTS
The primary outcome was 30%. The secondary outcome was 3%, while six patients (5%) were referred to a dentist for suspected ONJ.
CONCLUSION
There appears to be a continued benefit when intravenous bisphosphonates are given for longer than 21 months.
目的
评估接受静脉注射双膦酸盐治疗超过21个月的多发性骨髓瘤、转移性乳腺癌、前列腺癌或肺癌患者骨骼并发症的发生率。
方法
主要结局是治疗21个月后至少发生一次骨相关事件（SRE）的诊断。次要结局是颌骨坏死（ONJ）的发生率。
结果
主要结局为30%。次要结局为3%，同时有6名患者（5%）因疑似ONJ转诊至牙医处。
结论
静脉注射双膦酸盐治疗超过21个月似乎持续有益。
Zotero 插件